Valuation: Valneva

Capitalization 465M 546M 430M 405M 754M 50.74B 770M 5.05B 1.97B 24.37B 2.05B 2B 86.82B P/E ratio 2026 *
-7.23x
P/E ratio 2027 * 5.75x
Enterprise value 588M 690M 544M 513M 955M 64.22B 974M 6.39B 2.5B 30.84B 2.59B 2.54B 110B EV / Sales 2026 *
3.56x
EV / Sales 2027 * 1.62x
Free-Float
86.07%
Yield 2026 *
-
Yield 2027 * -
1 day+1.71%
1 week-1.29%
Current month-5.14%
1 month-45.70%
3 months-37.15%
6 months-40.87%
Current year-28.05%
1 week 2.53
Extreme 2.527
2.77
1 month 2.53
Extreme 2.527
5
Current year 2.53
Extreme 2.527
5.15
1 year 2.34
Extreme 2.34
5.42
3 years 1.73
Extreme 1.726
7.85
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Operating Officer 59 2023-12-31
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 64 2023-12-19
Change 5d. change 1-year change 3-years change Capi.($)
+1.71%-1.29%-4.46%-47.98% 535M
+1.74%+0.55%-1.27%-9.27% 44.74B
-1.20%-0.36%+48.65%+31.77% 34.75B
-0.89%+1.53%+34.43%+36.72% 29.82B
-0.97%-3.42%+16.84%-15.01% 28.37B
+0.22%-2.71%+186.40%+369.47% 19.07B
-1.01%+4.38%+66.94%+223.70% 14.93B
-1.59%-0.97%+74.81%+158.73% 14.32B
+2.31%-6.43%+3,777.83%+3,935.28% 13.93B
+0.25%-4.10%+37.01%+4.36% 13.17B
Average +0.06%-1.47%+423.72%+468.78% 21.36B
Weighted average by Cap. -0.07%-1.02%+289.61%+322.34%

Financials

2026 *2027 *
Net sales 165M 194M 153M 144M 268M 18.03B 274M 1.79B 702M 8.66B 728M 712M 30.85B 318M 373M 294M 277M 516M 34.68B 526M 3.45B 1.35B 16.65B 1.4B 1.37B 59.33B
Net income -63.72M -74.79M -58.97M -55.52M -103M -6.96B -106M -692M -271M -3.34B -281M -275M -11.9B 73.55M 86.34M 68.07M 64.09M 119M 8.03B 122M 799M 312M 3.86B 324M 317M 13.74B
Net Debt 123M 145M 114M 108M 200M 13.47B 204M 1.34B 524M 6.47B 544M 532M 23.05B 50.06M 58.76M 46.33M 43.62M 81.25M 5.46B 82.91M 543M 213M 2.62B 221M 216M 9.35B
Logo Valneva
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
26-04-10 2.675 +1.71% 720,442
26-04-09 2.630 -2.23% 1,099,425
26-04-08 2.690 +4.47% 1,271,782
26-04-07 2.575 -4.98% 1,397,450
26-04-02 2.710 -3.97% 1,402,527
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.675EUR
Average target price
5.975EUR
Spread / Average Target
+123.36%

Quarterly revenue - Rate of surprise